Additionally, the introduction of next-generation sequencing (NGS) testing into the clinical space has led to developments in prognostication of newly diagnosed AML as well as developments in targeted therapies, leveraging specific genetic mutations known to be associated with AML such as FLT3, IDH1, IDH2, and recently KMT2A [16]. Here, KMT2A is linked to acute myeloid leukemia.